Meta AnalysisID 3744
黄嘌呤氧化酶抑制剂别嘌醇对人类心血管系统的影响：系统评价和Meta分析
CRD42018089744
In patients with hyperuricemia, what is the effect of the xanthine-oxidase inhibitor allopurinol compared to placebo or other uric acid lowering drugs on cardiovascular outcomes and mortality?
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 3744
- Evidence Id
- 12302
- Core Evidence Id
- 12302
- Source Meta Analysis Id
- 3704
- Herb2 Meta Analysis Id
- HBMA003704
- Crd Id
- CRD42018089744
- Title
- Cardiovascular effects of the xanthine-oxidase inhibitor allopurinol in humans: a systematic review and meta-analysis
- Review Question
- In patients with hyperuricemia, what is the effect of the xanthine-oxidase inhibitor allopurinol compared to placebo or other uric acid lowering drugs on cardiovascular outcomes and mortality?
- Study Type Included
- Inclusion criteria: (Randomized) controlled trials, observational (cohort) studies (prospective or retrospective) Exclusion criteria: Case reports, N of one trials
- Condition Being Studied
- Hyperuricemia
- Participant
- Inclusion criteria: Adult human patients with hyperuricemia, without renal disease, with or without atherosclerosis and with or without gout. Exclusion criteria: Animal studies, in vitro studies, in sillico studies, studies in patients with renal disease (MDRD<30 ml/min), studies in patients younger than 18 years and patients with tumor lysis syndrome (these patients are not comparable with cardiovascular hyperurecemic patients, since they have normal uric acid levels at start of treatment, often have hematological disease and/or receive immunosupressive comedication, which can interfere immunological mechanisms of hypersensitivity syndrome, the most important adverse event)
- Animal
- Human Disease Modelled
- Intervention
- Inclusion criteria: Treatment with the xanthine oxidase inhibitor allopurinol, in any dose regime and treatment duration. Exclusion criteria: No allopurinol administered
- Comparator Control
- Inclusion criteria: Control group receiving placebo, no treatment, or other uric acid lowering drugs, for example benzbromaron Exclusion criteria: No appropriate control group present
- Main Outcome
- Incidence of cardiovascular mortality Incidence of myocardial infarction Incidence of stroke Combined incidence of cardiovascular mortality, myocardial infarction and stroke Measures of effect For all outcomes, we will include data measured from randomisation to the last available follow-up (expected range 2-250 weeks)
- Outcome Measure
- Additional Outcome
- none Measures of effect N/A
- Study Method
- Intervention, Meta-analysis, Narrative synthesis, Systematic review
- Keyword
- Cardiovascular System; Drug Hypersensitivity; Enzyme Inhibitors; Gout Suppressants; Humans; Xanthine Oxidase
- Contact
- Kimberley Wever [email protected]
- Organisational Affiliation
- Radboud university medical center
- Funding Source
- No dedicated funding
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- Netherlands
- Review Stage
- Review Completed not published
- First Submission Date
- 2018-02-27
- Registration Date
- 2018-03-01
- Anticipated Start Date
- 2018-02-26
- Anticipated Completion Date
- 2021-02-01
- Title Cn
- 黄嘌呤氧化酶抑制剂别嘌醇对人类心血管系统的影响：系统评价和Meta分析
- Title En
- Cardiovascular effects of the xanthine-oxidase inhibitor allopurinol in humans: a systematic review and meta-analysis
- Bilingual Status
- complete